Results 161 to 170 of about 3,241 (183)

Blastic Plasmacytoid Dendritic Cell Neoplasm

2015
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive tumor of plasmacytoid dendritic cells that commonly presents with involvement of the skin, bone marrow, peripheral blood, and lymph nodes. This diagnosis portends a dismal prognosis.
Amrita Goyal, Joi B. Carter, Lyn McDivitt Duncan   +2 more
openaire   +1 more source

Blastic plasmacytoid dendritic cell neoplasm

Dermatologie pro praxi, 2021
Michala Kučerová, Tomáš Kohoutek
openaire   +1 more source

Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review

Journal of Oncology Pharmacy Practice, 2021
Yazan Samhouri
exaly  

Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm

Cancers, 2021
C Cameron Yin, Naveen Pemmaraju, M James You   +2 more
exaly  

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm

New England Journal of Medicine, 2019
Naveen Pemmaraju, Andrew A Lane, Sumithira Vasu   +2 more
exaly  

Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Biological Therapy, 2020
Mansour Alfayez, Naveen Pemmaraju
exaly  

Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm

New England Journal of Medicine, 2018
Sara A Monaghan, Steven H Swerdlow
exaly  

A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm

Cancer Cell, 2016
Michele Ceribelli, George W Wright, Stephen Forman   +2 more
exaly  

More on Blastic Plasmacytoid Dendritic-Cell Neoplasms

New England Journal of Medicine, 2019
Sara A Monaghan, Steven H Swerdlow
exaly  

<p>Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data</p>

OncoTargets and Therapy, 2020
Guillaume Beziat, Loic Ysebaert
exaly